http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0804926-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fe74855697fef20a2e98a9b005db19 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 1997-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d415f3650f7e65ba6d3fc5fdd2374c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_651940bc5bdfbc8d2926427459be50b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa7fe57d838a626e0ac4bfc6589bb3cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47f841c4f9c561d67a11c55dfd144410 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e18003a9050a4d46220c6cddda4773c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7de85082f8dc6f4a26c99d9e90925f05 |
| publicationDate | 1997-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0804926-A1 |
| titleOfInvention | Combined preparation for treating male hypogonadism and men with hypophysal disorders |
| abstract | The invention relates to combination preparations which contain biogenic or synthetic androgens and biogenic or synthetic estrogens for the treatment of the deflections of testosterone metabolism in old age, hypogonadal men and men with pituitary disorders.n n n The combination preparations are in various galenical forms of preparation, e.g. B. ointments, gels, sprays, TTS systems, tablets, dragees, capsules and suppositories. With these preparations, the deflections of the testosterone metabolism in old age, in disease states, for. B. pituitary diseases (adenoma), hypogonadism and / or metabolic syndrome treated to maintain the balance between androgens and estrogens, similar to young, healthy men, including sick and / or old men.n n n The agent for treating the imbalances is administered orally, parenterally, percutaneously, sublingually or rectally, depending on the galenic form. This avoids unphysiological changes in steroid-converting enzymes, such as aromatases and reductases, and significantly increases the success of therapy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9952533-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6503894-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6645954-B2 |
| priorityDate | 1996-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 418.